Results 11 to 20 of about 780 (156)

The Antiviral Efficacy and Safety of Azvudine in Hospitalized SARS‐CoV‐2 Infected Patients with Liver Diseases Based on a Multicenter, Retrospective Cohort Study [PDF]

Advanced Science
Despite azvudine being prioritized for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, its effectiveness and safety remain inadequately substantiated in hospitalized SARS‐CoV‐2 infected patients with liver ...
Junyi Sun, Mengzhao Yang, Guanyue Su, Ling Wang, Xiaobo Hu, Yongjian Zhou, Guangying Cui, Guowu Qian, Yiqiang Yuan, Xinjun Hu, Silin Li, Hong Luo, Shixi Zhang, Guangming Li, Donghua Zhang, Guotao Li, Ming Cheng, Zujiang Yu, Zhigang Ren   +18 more
doaj   +3 more sources

Real-World Evaluation Study of Azvudine for the Treatment of Patients With COVID-19: A Systematic Review and Meta-Analysis [PDF]

Canadian Journal of Infectious Diseases and Medical Microbiology
Conclusions: Azvudine significantly reduced the hospitalization time and the time to nucleic acid conversion to negative in COVID-19 patients and significantly lowered all-cause mortality (Grading of Recommendations Assessment, Development, and ...
Abiden Kapar, Huling Li, Qian He, Dandan Lin, Dandan Tang, Kai Peng, Yida Wang, Kai Wang   +7 more
doaj   +3 more sources

Effectiveness and safety of azvudine versus nirmatrelvir/ritonavir in hospitalized patients with COVID-19 [PDF]

BMC Infectious Diseases
Purpose To compare the effectiveness and safety of two antiviral drugs, azvudine and nirmatrelvir/ritonavir, in treating hospitalized patients with COVID-19.
Jin Yang, Jiao Min, Ling Ding, Rong Liu, Ya Yang, Jian-feng Zhang, Wei Lei   +6 more
doaj   +4 more sources

Advances in the effectiveness and safety of azvudine treatment: a comprehensive review [PDF]

Frontiers in Pharmacology
The global impact of COVID-19 has highlighted the urgent need for effective therapeutic interventions against SARS-CoV-2. Azvudine, a dual-target nucleoside drug initially developed for human immunodeficiency virus (HIV), has gained attention for its ...
Jiayi Li, Jiayi Li, Bo Zhu, Bo Zhu, Jian Lu, Zheyi Dong, Ping Li, Wenge Li, Chunfu Zheng, Junbiao Chang, Shunlai Shang, Shunlai Shang   +11 more
doaj   +4 more sources

Azvudine efficacy in reducing mortality in COVID-19 patients [PDF]

European Journal of Medical Research
Background Several therapeutic drugs have been authorized for the treatment of patients with Coronavirus disease 2019 (COVID-19). However, further research on the mechanisms of action, efficacy, and target populations of these novel therapeutic drugs are
Zhen Zhong, Xiao-feng Liu, Xiao-zhong Zhou, Jia-ning Zhong, Li-cheng Zhou, Rong Li, Xian-fa Liu   +6 more
doaj   +4 more sources

Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19 [PDF]

BMJ Open Respiratory Research
Background In China, both nirmatrelvir-ritonavir (Paxlovid) and azvudine have been granted approval to treat adult SARS-CoV-2-infected patients with moderate symptoms.
Junjun Chen, Zheng Zhang, Huan Zhang, Yao Li, Yan Kang, Jianbo Li, Tan Xiaojiao, Chenxi Wang, Haiqing Shi, Xiaodong Jin, Xuelian Liao   +10 more
doaj   +4 more sources

Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study

Acta Pharmaceutica Sinica B, 2023
In our retrospective cohort study, we aim to explore whether Azvudine modifies the risk of death in COVID-19 patients. It was conducted on the medical records of patients, consecutively admitted for COVID-19 pneumonia to two hospitals in Chongqing, China.
Kaican Zong, Hui Zhou, Wen Li, E Jiang, Yi Liu, Shiying Li   +5 more
doaj   +3 more sources

Systematic evaluation of therapeutic effectiveness of Azvudine in treating COVID-19 hospitalized patients: a retrospective cohort study [PDF]

Frontiers in Cellular and Infection Microbiology
BackgroundAzvudine, a repurposed oral small molecule antiviral drug, has potential effects in combating the SARS-CoV-2 virus. However, studies on its clinical efficacy in patients with COVID-19 are still limited and controversial, and further research ...
Yingkai Xu, Yingkai Xu, Yuan Huang, Zihan Yuan, Zihan Yuan, Wanbing Liu, Li Wang, Lei Liu   +7 more
doaj   +4 more sources

Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants

Frontiers in Pharmacology, 2023
Background: Azvudine (FNC) is a promising treatment candidate for managing coronavirus disease 2019 (COVID-19). However, drug interactions with azvudine have been poorly studied, especially with no reported cases of azvudine with anticoagulants such as ...
Xi Zhang, Fengwei Jiao, Guangrun Li, Xiaojia Yu, Yuqing Pei, Ying Zhang, Zihui Wang, Zihui Wang, Pengfei Li   +8 more
doaj   +3 more sources

Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine

Frontiers in Cellular and Infection Microbiology, 2023
BackgroundAzvudine has been approved in China for the treatment of COVID-19 patients. Previous studies have suggested a correlation between high levels of lactate dehydrogenase (LDH) and the severity of COVID-19.
Manyun Mao, Manyun Mao, Manyun Mao, Manyun Mao, Manyun Mao, Yating Dian, Yating Dian, Yating Dian, Yating Dian, Yating Dian, Yuming Sun, Yuming Sun, Yuming Sun, Yuming Sun, Yuming Sun, Wangqing Chen, Wangqing Chen, Wangqing Chen, Wangqing Chen, Wangqing Chen, Wu Zhu, Wu Zhu, Wu Zhu, Wu Zhu, Wu Zhu, Guangtong Deng, Guangtong Deng, Guangtong Deng, Guangtong Deng, Guangtong Deng   +29 more
doaj   +3 more sources